New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines announced that the New England Journal of Medicine has published Phase 1/2 clinical trial data on their drug RASONQUE (daraxonrasib) in treating RAS mutant non-small cell lung cancer (NSCLC). The study showed promising objective response and disease control rates with a manageable safety profile. The data supports the ongoing P…